Cervical cancer multidrug resistance cell strain established by etoposide induction
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
- Publication Date
- 2009-08-12
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of tumor biology and relates to a drug-resistant cell line of human cervical cancer. Specifically, it involves using human cervical cancer SiHa as the parent cell, and establishing the cervical cancer multi-drug resistant cell line SiHa / VP16 by gradually increasing the concentration of the chemotherapeutic drug etoposide (VP16). Background technique
[0002] Cervical cancer seriously endangers women's health, and its incidence rate ranks second among female malignant tumors. There are about 500,000 new cases of cervical cancer in the world every year, and the number of new cases in my country accounts for about 1 / 3 of the total number of cases in the world. Chemotherapy is an important method for the treatment of cervical cancer, but a common and difficult problem in chemotherapy is the generation of multidrug resistance, that is, the phenomenon of cross-resistance of tumors to multiple chemotherapeutic drugs with di...